Advertisement
Oxcarbazepine is indicated for the use in monotherapy or adjunctivetherapy for the treatment of partial seizures in adults and as monotherapy inthe treatment of partial seizures in children aged 4 years and above withepilepsy, and as adjunctive therapy in children aged 4 years and above withepilepsy. This new product is bioequivalent to Trileptal(R), a registeredtrademark of Novartis. Trileptal(R) had U.S. sales of approximately $640million for the 12-month period ended June 30, 2007, according to IMS Data.Caraco has three strengths available, 150 mg, 300 mg and 600 mg.
Advertisement
Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are pleasedto be one of the first companies to market oxcarbazepine. We continue to focuson working towards expanding our product offering as quickly and effectivelyas possible. This will bring our total product selection to 42 differentproducts represented by 89 various strengths."
Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops,manufactures, markets and distributes generic and private-labelpharmaceuticals to the nation's largest wholesalers, distributors, drugstorechains and managed care providers.
Safe Harbor: This news release contains forward-looking statements madepursuant to the safe-harbor provisions of the Private Securities LitigationReform Act of 1995. Such statements are based on management's currentexpectations and are subject to risks and uncertainties that could causeactual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in theCorporation's filings with the Securities and Exchange Commission and include,but are not limited to: information of a preliminary nature that may besubject to adjustment, potentially not obtaining or delay in obtaining FDAapproval for new products, governmental restrictions on the sale of certainproducts, development by competitors of new or superior products or cheaperproducts or new technology for the production of products, the entry into themarket of new competitors, market and customer acceptance and demand for newpharmaceutical products, availability of raw materials, timing and success ofproduct development and launches, dependence on few products generatingmajority of sales, product liability claims for which the Company may beinadequately insured, and other risks identified in this report and from timeto time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. Wedisclaim, however, any intent or obligation to update our forward-lookingstatements.
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
